Catabasis Pharmaceuticals Inc


H.C. Wainwright Slashes Catabasis Pharmaceuticals Inc (CATB) Price Target in Half, But Sticks with Buy Rating

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares are falling almost 8% amid an unfortunate setback with the firm’s MoveDMD Part B data read-out that failed …

Catabasis Pharmaceuticals Inc (CATB) Is in Rollercoaster Mode

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares are falling 16% today after having just risen approximately 80% last week, placing the biotech stock in full …

Oppenheimer Waits for Catabasis Pharmaceuticals Inc (CATB) to Present Longer Term Data in DMD

Yesterday evening, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced that lead candidate edasalonexent missed the primary endpoint in its Phase II proof-of-concept trial in Duchenne …

Cowen Downgrades Catabasis Pharmaceuticals Inc (CATB), Slashes The Price Target To $4

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares lost over 70% of their value today after the company reported final results from Part B of its …

Cowen Reiterates Upbeat View on Sarepta Therapeutics Inc (SRPT) Amid Pipeline Collaborations

Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …

William Blair Bullish on Sarepta Therapeutics Inc (SRPT) Amid First Patient Dosing in Phase III Trial and Catabasis Partnership

On Wednesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it has dosed the first patient in the Phase III ESEENCE trial for patients with …

Analysts Chime in on Two Volatile Biotech Stocks: Catabasis Pharmaceuticals Inc (CATB), Alcobra Ltd (ADHD)

The biotech world is full of news today, and analysts are accordingly prompted to share insights on Catabasis Pharmaceuticals Inc (NASDAQ:CATB)¬†and¬†Alcobra Ltd (NASDAQ:ADHD). …